Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-12 09:08 am Purchase |
2025-03-31 | 13G | Seadrill Limited SDRL |
Adage Capital Management, L.P. | 4,200,535 6.760% |
771,366 (+22.49%) |
Filing History |
| 2025-05-12 09:07 am Sale |
2025-03-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Adage Capital Management, L.P. | 8,201,344 7.600% |
-1,425,960 (-14.81%) |
Filing History |
| 2025-05-12 09:07 am Sale |
2025-03-31 | 13G | ProQR Therapeutics N.V. PRQR |
Adage Capital Management, L.P. | 8,102,098 7.700% |
-1,500,182 (-15.62%) |
Filing History |
| 2025-05-12 09:06 am Purchase |
2025-03-31 | 13G | Wave Life Sciences Ltd. WVE |
Adage Capital Management, L.P. | 12,516,500 8.150% |
12,516,500 (New Position) |
Filing History |
| 2025-05-12 09:06 am Purchase |
2025-03-31 | 13G | Soleno Therapeutics, Inc. SLNO |
Adage Capital Management, L.P. | 4,392,696 9.580% |
1,070,550 (+32.22%) |
Filing History |
| 2025-05-12 09:05 am Purchase |
2025-03-31 | 13G | Praxis Precision Medicines, Inc. PRAX |
Adage Capital Management, L.P. | 1,742,758 8.640% |
888,675 (+104.05%) |
Filing History |
| 2025-05-12 09:05 am Purchase |
2025-03-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
Adage Capital Management, L.P. | 5,697,605 6.430% |
5,697,605 (New Position) |
Filing History |
| 2025-05-12 09:04 am Purchase |
2025-03-31 | 13G | Solid Biosciences Inc. SLDB |
Adage Capital Management, L.P. | 6,729,484 8.680% |
4,975,325 (+283.63%) |
Filing History |
| 2025-05-12 09:04 am Purchase |
2025-03-31 | 13G | Cidara Therapeutics, Inc. CDTX |
Adage Capital Management, L.P. | 990,000 9.040% |
990,000 (New Position) |
Filing History |
| 2025-05-12 09:03 am Purchase |
2025-03-31 | 13G | Ensysce Biosciences, Inc. ENSC |
Adage Capital Management, L.P. | 74,711 5.320% |
74,711 (New Position) |
Filing History |
| 2025-05-12 09:03 am Purchase |
2025-03-31 | 13G | Centessa Pharmaceuticals plc CNTA |
Adage Capital Management, L.P. | 6,954,000 5.220% |
6,954,000 (New Position) |
Filing History |
| 2025-05-12 09:02 am Purchase |
2025-03-31 | 13G | Traws Pharma, Inc. TRAW |
Adage Capital Management, L.P. | 330,000 6.500% |
330,000 (New Position) |
Filing History |
| 2025-05-12 09:02 am Sale |
2025-03-31 | 13G | UroGen Pharma Ltd. URGN |
Adage Capital Management, L.P. | 1,277,000 2.770% |
-1,651,086 (-56.39%) |
Filing History |
| 2025-05-12 09:02 am Purchase |
2025-03-31 | 13G | Aeva Technologies, Inc. AEVA |
Adage Capital Management, L.P. | 1,401,454 2.560% |
1,401,454 (New Position) |
Filing History |
| 2025-05-12 09:01 am Sale |
2025-03-31 | 13G | Protara Therapeutics, Inc. TARA |
Adage Capital Management, L.P. | 0 0.000% |
-2,250,000 (Position Closed) |
Filing History |
| 2025-05-12 09:01 am Purchase |
2025-03-31 | 13G | Mereo BioPharma Group plc MREO |
Adage Capital Management, L.P. | 8,503,780 1.070% |
8,503,780 (New Position) |
Filing History |
| 2025-05-12 09:00 am Sale |
2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Adage Capital Management, L.P. | 237,953 0.700% |
-1,971,662 (-89.23%) |
Filing History |
| 2025-05-12 09:00 am Purchase |
2025-03-31 | 13G | Abeona Therapeutics Inc. ABEO |
Adage Capital Management, L.P. | 4,411,572 8.780% |
201,143 (+4.78%) |
Filing History |
| 2025-02-12 09:46 am Purchase |
2024-12-31 | 13G | ProQR Therapeutics N.V. PRQR |
Adage Capital Management, L.P. | 9,602,280 9.300% |
9,602,280 (New Position) |
Filing History |
| 2025-02-12 09:45 am Purchase |
2024-12-31 | 13G | Monopar Therapeutics Inc. MNPR |
Adage Capital Management, L.P. | 599,195 9.860% |
599,195 (New Position) |
Filing History |